Spinal cord (SC) damage is central to multiple sclerosis (MS) progression but remains difficult to quantify with conventional magnetic resonance imaging (MRI).
To characterize upper cervical SC pathology using quantitative MRI (qMRI) and assess longitudinal changes and predictors of clinical progression and...
Kornelius Kaim, M. Ocampo-Pineda, C. Tsagkas et al.· Multiple Sclerosis Journal -...· 0 citations
Susceptibility-based MRI biomarkers, including paramagnetic rim lesions (PRLs) and central vein sign (CVS), were incorporated into the 2024 McDonald criteria because they improve diagnostic specificity in adult-onset MS; however, their role in pediatric-onset MS (POMS) remains incompletely defined. To synthesize curren...
Anna de Mauro, Rosa Cortese, Giulia Fadda et al.· Journal of Neurology· 0 citations
Inducing antigen-specific immune tolerance is a long-standing aim in organ-specific autoimmune diseases including multiple sclerosis (MS). We developed a therapy based on autologous red blood cells (RBCs) as tolerizing carriers of autoantigens and tested these in an open-label, dose-escalation, phase Ib clinical trial...
Andreas Lutterotti, Thomas Ludersdorfer, M. Docampo et al.· Proceedings of the National...· 1 citation
Sormani et al. argue that multiple sclerosis should be viewed as a biological continuum rather than distinct clinical forms. Evidence from recent trials suggests that therapies targeting shared biological mechanisms can slow disability progression across the disease spectrum, supporting a shift away from traditional cl...
M. Sormani, Heinz Wiendl, X. Montalban et al.· Brain : a journal of neurolo...· 0 citations
Quantitative T1 mapping (qT1) is a magnetic resonance imaging (MRI) biomarker of brain microstructural changes; however, its application in Alzheimer disease (AD) remains limited. We compared cortico-limbic qT1 values between patients with AD and healthy controls (HCs) and examined their relationship with amyloid burde...
L. Gualco, N. Montobbio, M. Losa et al.· European Radiology Experimen...· 0 citations
It is suggested that serum GFAP may serve as a biomarker for personalized risk stratification and treatment monitoring and as a screening tool to reduce cohort size in clinical trials targeting MS progression.
M. Einsiedler, S. Sandgren, S. Schaedelin et al.· JAMA Neurology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.